Skip to main content
Clinical Trials/NCT01589432
NCT01589432
Completed
Phase 2

A Randomized, Double-blind, Placebo and Active-controlled Study of the Electrophysiological Effects of ABT-639 on Spontaneous Activity in C-Nociceptors in Patients With Painful Diabetic Peripheral Neuropathy

AbbVie (prior sponsor, Abbott)1 site in 1 country39 target enrollmentApril 2012

Overview

Phase
Phase 2
Intervention
ABT-639
Conditions
Diabetic Neuropathic Pain
Sponsor
AbbVie (prior sponsor, Abbott)
Enrollment
39
Locations
1
Primary Endpoint
Spontaneous activity in peripheral c-nociceptors
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

People with diabetes can, over time develop nerve damage throughout the body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms, feet and legs.

Registry
clinicaltrials.gov
Start Date
April 2012
End Date
November 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

ABT-639

Intervention: ABT-639

Placebo

Intervention: Placebo

Lidocaine

Intervention: Lidocaine

Outcomes

Primary Outcomes

Spontaneous activity in peripheral c-nociceptors

Time Frame: 10 minute intervals over 180 minutes

Spontaneous activity in peripheral c-nociceptor measured through microneurography

Secondary Outcomes

  • Pain intensity measurements(hourly for 4 hours)

Study Sites (1)

Loading locations...

Similar Trials